Ritholtz Wealth Management Purchases 4,218 Shares of Illumina, Inc. $ILMN

Ritholtz Wealth Management increased its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 288.1% during the third quarter, Holdings Channel reports. The fund owned 5,682 shares of the life sciences company’s stock after purchasing an additional 4,218 shares during the quarter. Ritholtz Wealth Management’s holdings in Illumina were worth $1,555,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Baker Tilly Wealth Management LLC boosted its stake in Illumina by 3.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after purchasing an additional 42 shares during the period. Ashton Thomas Securities LLC grew its position in Illumina by 3.3% in the 3rd quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock worth $369,000 after purchasing an additional 43 shares during the last quarter. Elevation Wealth Partners LLC grew its position in Illumina by 19.7% in the 3rd quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock worth $80,000 after purchasing an additional 48 shares during the last quarter. Evergreen Capital Management LLC grew its position in Illumina by 0.5% in the 3rd quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after purchasing an additional 50 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its stake in shares of Illumina by 2.2% in the third quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock valued at $686,000 after purchasing an additional 54 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Evercore reaffirmed an “underperform” rating on shares of Illumina in a report on Friday, October 30th. Leerink Partners boosted their price objective on Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Argus increased their price objective on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Citigroup raised their target price on Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research report on Monday, November 2nd. Finally, Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $244.24.

Get Our Latest Research Report on ILMN

Recent Illumina Headlines

Investors following ILMN have been watching these headlines:

  • Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
  • Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
  • Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing

Illumina Stock Performance

Shares of ILMN opened at $207.01 on Monday. Illumina, Inc. has a one year low of $112.65 and a one year high of $309.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. The stock has a market cap of $31.30 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 2.81 and a beta of 1.46. The company has a 50-day moving average of $249.02 and a two-hundred day moving average of $179.64.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period last year, the company posted $1.34 earnings per share. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Keith Meister sold 299,336 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. This trade represents a 17.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 1,881,899 shares of company stock valued at $415,905,954. Corporate insiders own 2.90% of the company’s stock.

About Illumina

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.